Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323177 | 0.94 | KIT (0.64) | KITFGFR1ABL1KDREGFR | |
| SCHEMBL18323158 | 0.78 | KIT (0.62) | KITFGFR1ABL1KDREGFR | |
| SCHEMBL18323209 | 0.77 | KIT (0.51) | KITFGFR1ABL1KDRRET | |
| SCHEMBL15907229 | 0.77 | KIT (0.52) | KITFGFR1ABL1KDRBRAF | |
| SCHEMBL15907297 | 0.76 | KIT (0.43) | KITFGFR1ABL1KDRRET | |
| SCHEMBL24122650 | 0.76 | KIT (0.79) | KITFGFR1ABL1KDRBRAF | |
| SCHEMBL30011074 | 0.76 | KIT (0.79) | KITFGFR1ABL1KDRBRAF | |
| SCHEMBL24503732 | 0.75 | KIT (0.85) | KITFGFR1ABL1KDREGFR | |
| SCHEMBL18323290 | 0.73 | KIT (0.85) | KITFGFR1ABL1KDREGFR | |
| SCHEMBL15907164 | 0.73 | KIT (0.73) | KITFGFR1ABL1KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KIT 577/4885FGFR1 199/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.